Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym. Nivestym has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback